Nektar Therapeutics (NASDAQ:NKTR)’s share price was up 5.6% on Monday following insider buying activity. The company traded as high as $19.36 and last traded at $19.28, with a volume of 1,140,297 shares. The stock had previously closed at $18.26.

Specifically, Director Roy A. Whitfield purchased 35,000 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was purchased at an average price of $17.95 per share, for a total transaction of $628,250.00. Following the completion of the purchase, the director now directly owns 133,000 shares of the company’s stock, valued at $2,387,350. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $19.55, for a total value of $33,254.55. Following the completion of the transaction, the senior vice president now owns 32,803 shares of the company’s stock, valued at approximately $641,298.65. The disclosure for this sale can be found here. Insiders sold 154,803 shares of company stock valued at $3,229,297 in the last 90 days. Company insiders own 5.44% of the company’s stock.

Several research analysts have recently weighed in on NKTR shares. Jefferies Group LLC restated a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, July 21st. ValuEngine upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Roth Capital set a $31.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a research note on Monday, May 22nd. Zacks Investment Research upgraded Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Tuesday, August 1st. Finally, William Blair restated an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $26.78.

The company’s 50 day moving average price is $20.57 and its 200-day moving average price is $18.33. The stock’s market capitalization is $3.01 billion.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by $0.04. The business had revenue of $34.60 million during the quarter, compared to analyst estimates of $33.64 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The firm’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.36) EPS. On average, equities analysts forecast that Nektar Therapeutics will post ($0.99) EPS for the current year.

Institutional investors have recently modified their holdings of the company. Flinton Capital Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Flinton Capital Management LLC now owns 4,480 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 448 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Nektar Therapeutics by 14.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,603 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 692 shares during the period. Meadow Creek Investment Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock worth $145,000 after buying an additional 616 shares during the period. LS Investment Advisors LLC raised its position in shares of Nektar Therapeutics by 8.8% in the second quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 535 shares during the period. Finally, Glen Harbor Capital Management LLC raised its position in shares of Nektar Therapeutics by 11.1% in the first quarter. Glen Harbor Capital Management LLC now owns 7,840 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 784 shares during the period. Institutional investors own 93.02% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/nektar-therapeutics-nktr-trading-up-5-6-on-insider-buying-activity/1487821.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.